By Mill Chart
Last update: Jan 4, 2024
Discover GILEAD SCIENCES INC (NASDAQ:GILD), an undervalued stock highlighted by our stock screener. NASDAQ:GILD showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:GILD has achieved a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:GILD, the assigned 8 is noteworthy for profitability:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has achieved a 5 out of 10:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:GILD scores a 4 out of 10:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
Check the latest full fundamental report of GILD for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GILEAD SCIENCES INC
NASDAQ:GILD (4/19/2024, 3:58:09 PM)
After market: 66.76 0 (0%)66.76
+0.6 (+0.91%)
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Dividend stocks can be a smart way to ride out market volatility.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...
Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects.